|
|
|
|
|||||
|
|
|
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.
Conference Call and Webcast Information:
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
| 4 hours | |
| May-05 | |
| Mar-19 | |
| Mar-19 | |
| Mar-19 | |
| Mar-12 | |
| Mar-12 | |
| Mar-09 | |
| Mar-09 | |
| Mar-09 | |
| Mar-09 | |
| Mar-09 | |
| Feb-26 | |
| Jan-12 | |
| Dec-22 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite